POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid volume, acid-base balance, and nerve impulse transmission. Dextrose provides caloric supplementation and sodium chloride maintains extracellular fluid volume and electrolyte balance. The combination corrects electrolyte and fluid deficits.
| Metabolism | Potassium chloride is not metabolized; potassium is excreted primarily by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle. |
| Excretion | Renal: potassium >90% excreted in urine (glomerular filtration, distal tubular secretion); chloride 95% renally; dextrose nearly completely reabsorbed; sodium >99% renally with reabsorption. |
| Half-life | Potassium: 2-4 hours (plasma, no true terminal t½ due to rapid equilibration with intracellular stores); clinical context: half-life prolonged in renal impairment. |
| Protein binding | Potassium: 0% unbound; chloride: 0% unbound; dextrose: 0%; sodium: 0%. |
| Volume of Distribution | Potassium: 0.4-0.6 L/kg (total body water); clinical meaning: reflects distribution into intracellular fluid (98% body potassium is intracellular). |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: within minutes for potassium repletion (cardiac effects seen in seconds with ECG changes). |
| Duration of Action | Intravenous: 2-4 hours for electrolyte effects; duration depends on infusion rate and total dose; continuous infusion required for sustained repletion. |
Intravenous infusion; dose depends on serum potassium levels and body weight. Typical adult maintenance: 10-20 mEq/hour, not exceeding 40 mEq/hour or 200 mEq/day. Concentration used: 0.3% potassium chloride (40 mEq/L) in D5 0.2% NaCl.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR <30 mL/min: Reduce dose by 50% and monitor serum potassium closely. Avoid if GFR <10 mL/min unless severe hypokalemia. For GFR 30-50 mL/min: Use with caution, reduce dose by 25%. |
| Liver impairment | No specific Child-Pugh based adjustments. However, in severe hepatic impairment (Child-Pugh C), use with caution due to risk of hyperkalemia and fluid overload; monitor potassium levels frequently. |
| Pediatric use | Weight-based: 0.2-0.5 mEq/kg/hour intravenously; maximum rate 0.5 mEq/kg/hour. For maintenance: 2-3 mEq/kg/day. Adjust based on serum potassium monitoring. |
| Geriatric use | Elderly patients may have reduced renal function; start at lower end of dosing (e.g., 10 mEq/hour) and titrate based on potassium levels and renal function. Monitor for fluid overload due to dextrose and sodium content. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium chloride and sodium chloride are normal milk constituents; dextrose infusion may raise maternal blood glucose modestly, but glucose transfer to milk is low. No specific M/P ratio reported; these components are not contraindicated in breastfeeding. Monitor maternal glucose and potassium levels. |
| Teratogenic Risk | Potassium chloride, dextrose, and sodium chloride at these concentrations pose minimal fetal risk when used as maintenance fluids. No specific teratogenicity is associated with potassium chloride or 5% dextrose/0.2% sodium chloride. However, maternal hyperglycemia from dextrose may increase risk of neural tube defects and macrosomia in first trimester; fetal/neonatal hypoglycemia with excessive dextrose infusion. Potassium imbalance (hyper/hypokalemia) may affect fetal cardiac function. Generally considered safe when maternal electrolyte balance is maintained. |
■ FDA Black Box Warning
No FDA boxed warning for this specific combination product. However, potassium chloride products in general carry a warning about rapid infusion causing hyperkalemia and cardiac arrest.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Severe renal impairment with oliguria or anuria","Concurrent use with potassium-sparing diuretics (e.g., spironolactone, amiloride)","Hypersensitivity to any component","Addison's disease (if causing hyperkalemia)","Acute dehydration (if causing hyperkalemia)"]
| Precautions | ["Monitor serum potassium, glucose, and electrolytes regularly","Use caution in renal impairment, heart failure, or conditions predisposing to hyperkalemia","Risk of hyperkalemia if administered too rapidly or in patients with impaired renal function","Avoid in patients with elevated potassium levels","Use with caution in patients receiving potassium-sparing diuretics or ACE inhibitors"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum potassium, sodium, glucose, renal function, and fluid status. Fetal monitoring indicated for signs of electrolyte imbalance or fluid overload (e.g., nonstress test or biophysical profile in high-risk pregnancies). Assess for maternal edema, hypertension, or signs of hyper/hypokalemia (ECG changes). |
| Fertility Effects | No known effects on fertility or reproductive function. Potassium chloride, dextrose, and sodium chloride at these concentrations do not alter fertility based on animal studies and clinical experience. |